News

A survey of ENT clinicians reveals variability in managing chronic rhinosinusitis with nasal polyps, including steroid ...
Chronic rhinosinusitis with nasal polyps increases the likelihood of developing coexisting conditions, such as asthma, ...
A study published in July 2025 issue of Journal of Allergy and Clinical Immunology Global highlighted persistent challenges ...
Upstream Bio has dosed the first subject in the Phase II trial of verekitug in individuals with chronic obstructive pulmonary disease (COPD).
GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.
GSK's six-monthly IL-5 inhibitor depemokimab clears two phase 3 trials in chronic rhinosinusitis with nasal polyps (CRSwNP), its second indication.
If AZ has to wait for the results of that second trial it will allow Dupixent to consolidate its position, and perhaps more significantly for Fasenra's prospects in CRSwNP allow Nucala to build ...